Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

European Urology
Mauro GacciFrançois Giuliano

Abstract

Several preclinical reports, randomized controlled trials, systematic reviews, and posthoc analyses corroborate the role of phosphodiesterase type 5 inhibitors (PDE5-Is) in the treatment of men with lower urinary tract symptoms (LUTS) associated with benign prostatic enlargement (BPE). Update of the latest evidence on the mechanisms of action, evaluate the current meta-analyses, and emphasize the results of pooled data analyses of PDE5-Is in LUTS/BPE. Literature analysis of basic researches on PDE5-Is, systematic literature search in PubMed and Scopus until May 2015 on reviews of trials on PDE5-Is, and collection of pooled data available on tadalafil 5mg. Latest evidences on the pathophysiology of LUTS/BPE has provided the rationale for use of PDE5-Is: (1) improvement of LUT oxygenation, (2) smooth muscle relaxation, (3) negative regulation of proliferation and transdifferentiation of LUT stroma, (4) reduction of bladder afferent nerve activity, and (5) down-regulation of prostate inflammation are the proven mechanisms of action of PDE5-Is. Data from eight systematic reviews demonstrated that PDE5-Is allow to improve LUTS (International Prostate Symptom Score mean difference vs placebo: 2.35-4.21) and erectile function (Interna...Continue Reading

References

Jan 1, 1984·Urological Research·J P Nørgaard, J C Djurhuus
Dec 10, 2003·Urology·Karl Erik Andersson
Oct 29, 2005·The Journal of Comparative Neurology·Gert Holstege
Apr 22, 2008·European Urology·Christopher R ChappleClaus G Roehrborn
Nov 6, 2009·The Journal of Sexual Medicine·Annamaria MorelliMario Maggi
Feb 23, 2010·The Journal of Urology·Anthony Kanai, Karl-Erik Andersson
Jul 5, 2012·The Journal of Sexual Medicine·Javier AnguloIñigo Sáenz de Tejada
Oct 13, 2012·The Journal of Sexual Medicine·Linda VignozziMario Maggi
Aug 7, 2013·Organogenesis·Jane E Eastham, James I Gillespie
Oct 15, 2013·International Journal of Urology : Official Journal of the Japanese Urological Association·Ryuji SakakibaraMasashi Yano
Nov 28, 2013·Neurourology and Urodynamics·Conrad C MaciejewskiPeter D Metcalfe

❮ Previous
Next ❯

Citations

Apr 21, 2016·Expert Opinion on Drug Metabolism & Toxicology·Joshua A CohnRoger R Dmochowski
Aug 1, 2016·The Urologic Clinics of North America·Claudius Füllhase, Marc P Schneider
Apr 7, 2017·Journal of Endourology·Yunjin BaiJia Wang
Aug 24, 2017·The Aging Male : the Official Journal of the International Society for the Study of the Aging Male·Toshiyasu AmanoTakahiro Kishikage
Nov 23, 2017·International Journal of Urology : Official Journal of the Japanese Urological Association·Yoshihisa MatsukawaMomokazu Gotoh
Nov 15, 2017·Nature Reviews. Urology·Fabiola Z Mónica, Edson Antunes
Jul 12, 2018·BJU International·Adam WigginsLaurence A Levine
Jan 30, 2018·The Aging Male : the Official Journal of the International Society for the Study of the Aging Male·Aldo E CalogeroSandro La Vignera
Jan 18, 2019·The Aging Male : the Official Journal of the International Society for the Study of the Aging Male·Kyungtae KoDae Yul Yang
Aug 31, 2019·Current Urology Reports·Hanson Zhao, Howard H Kim
Nov 2, 2017·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Robert KüglerRalf Middendorff
Oct 4, 2020·Journal of Cellular and Molecular Medicine·Weixiang HeXinhua Zhang
Jun 14, 2020·Wiener klinische Wochenschrift·Rahat UllahXiaohui Zhou
Nov 21, 2018·The Aging Male : the Official Journal of the International Society for the Study of the Aging Male·Daisuke WatanabeAkio Mizushima
Jul 28, 2017·International Journal of Urology : Official Journal of the Japanese Urological Association·Yukio HommaKenji Maeda
Apr 25, 2018·Prostate Cancer and Prostatic Diseases·M SamarinasS Gravas
Jun 3, 2018·Current Urology Reports·Cosimo De NunzioAndrea Tubaro
Oct 12, 2018·Expert Opinion on Pharmacotherapy·Riccardo Bientinesi, Emilio Sacco
Oct 23, 2020·Current Urology Reports·Cora FogaingLysanne Campeau
Jul 1, 2020·European Journal of Pharmacology·Shogo ShimizuMotoaki Saito
Dec 22, 2020·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Wesam S AhmedKabir H Biswas
Feb 9, 2021·Current Urology Reports·Granville L LloydAnna Malykhina

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.